GDNF administration induces recovery of the nigrostriatal dopaminergic system both in young and aged parkinsonian mice
- 1 July 1998
- journal article
- research article
- Published by Wolters Kluwer Health in NeuroReport
- Vol. 9 (10) , 2365-2369
- https://doi.org/10.1097/00001756-199807130-00039
Abstract
GLIAL cell line-derived neurotrophic factor (GDNF) is a member of the transforming growth factor β superfamily and acts as a neurotrophic factor for the nigrostriatal dopaminergic system. GDNF was injected stereotaxically into the striatum of young (2 months old) and aged (12 months old) C57BL/6 mice that were treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) 1 week earlier. Immunocytochemical and neurochemical analyses showed significant recovery of the nigrostriatal dopaminergic system both in young and in aged mice. Since Parkinson's disease is a neurodegenerative disorder mainly affecting elderly people, this result demonstrates the potential usefulness of GDNF in treating Parkinson's disease.Keywords
This publication has 10 references indexed in Scilit:
- The coming of age of the GDNF family and its receptors: gene delivery in a rat Parkinson model may have clinical implicationsTrends in Neurosciences, 1997
- Glial cell line-derived neurotrophic factor induces the dopaminergic and cholinergic phenotype and increases locomotor activity in aged Fischer 344 ratsNeuroscience, 1997
- Parkinson's disease, trophic factors, and adrenal medullary chromaffin cell grafting: Basic and clinical studiesBrain Research Bulletin, 1996
- GDNF reduces apoptosis in dopaminergic neurons in vitroNeuroReport, 1995
- GDNF protects nigral dopamine neurons against 6-hydroxydopamine in vivoBrain Research, 1995
- The Trophic Cocktail Made by Adrenal Chromaffin CellsExperimental Neurology, 1993
- Long-term effect of MPTP in the mouse brain in relation to aging: neurochemical and immunocytochemical analysisBrain Research, 1990
- GM1 ganglioside treatment promotes recovery of striatal dopamine concentrations in the mouse model of MPTP-induced ParkinsonismExperimental Neurology, 1989
- Long-term effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on striatal dopamine content in young and mature miceJournal of the Neurological Sciences, 1987
- Parkinsonism Induced By 1-Methyl-4-Phenyl-1, 2, 3, 6-Tetrahydropyridine (MPTP): Implications for Treatment and the Pathogenesis of Parkinson’s DiseaseCanadian Journal of Neurological Sciences, 1984